Invesco
CATX icon

Invesco’s Perspective Therapeutics CATX Stock Holding History

Invesco’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Sell
52,866
-178,489
-77% -$674K ﹤0.01% 3621
2026
Q1 		$965K Buy
231,355
+207,077
+853% +$875K ﹤0.01% 2881
2025
Q4 		$66.8K Sell
24,278
-434
-2% -$1.24K ﹤0.01% 3676
2025
Q3 		$84.8K Buy
24,712
+2,503
+11% +$9.13K ﹤0.01% 3702
2025
Q2 		$76.4K Sell
22,209
-533
-2% -$1.41K ﹤0.01% 3682
2025
Q1 		$48.4K Sell
22,742
-2,432
-10% -$7.3K ﹤0.01% 3700
2024
Q4 		$80.3K Buy
25,174
+587
+2% +$4.79K ﹤0.01% 3649
2024
Q3 		$328K Buy
24,587
+1,064
+5% +$14.2K ﹤0.01% 3388
2024
Q2 		$235K Buy
+23,523
New +$340K ﹤0.01% 3573
2019
Q1 		– Sell
-1,632
Closed -$5K – 3716
2018
Q4 		$5K Sell
1,632
-93
-5% -$398 ﹤0.01% 3792
2018
Q3 		$9K Buy
1,725
+100
+6% +$557 ﹤0.01% 3866
2018
Q2 		$7K Buy
+1,625
New +$7.52K ﹤0.01% 3860
2014
Q4 		– Sell
-2,908
Closed -$49K – 4073
2014
Q3 		$49K Buy
+2,908
New +$72K ﹤0.01% 3962

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Invesco's CATX Position: Q2 2026 in Review

Invesco reduced its Perspective Therapeutics (CATX) stake by 77% in Q2 2026, selling an estimated $674K and leaving 52,866 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Invesco first reported a position in CATX in Q3 2014 and has held it in 13 quarters since. The position peaked at $965K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Invesco held 52,866 shares of Perspective Therapeutics worth $180K as of Q2 2026.
  • Invesco sold 178,489 Perspective Therapeutics shares in Q2 2026, an estimated $674K.
  • Perspective Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3621 holding.
  • Invesco first reported a position in Perspective Therapeutics in Q3 2014 and has held it in 13 quarters since.
  • Invesco's Perspective Therapeutics position peaked at $965K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.